CD3-NEGATIVE CELL POPULATION EXPRESSING CHEMOKINE RECEPTOR AND CELL ADHESION MOLECULE, USE THEREOF, AND METHOD FOR PRODUCING SAME

The present invention relates to an immunocyte having higher cytotoxic activity, and a pharmaceutical composition for NK cell therapies, for which high effect can be expected. The present invention provides a cell population including CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative ce...

Full description

Saved in:
Bibliographic Details
Main Authors YONEMITSU, Yoshikazu, HARADA, Yui
Format Patent
LanguageEnglish
French
German
Published 12.01.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to an immunocyte having higher cytotoxic activity, and a pharmaceutical composition for NK cell therapies, for which high effect can be expected. The present invention provides a cell population including CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells. The present invention provides the cell population, wherein the CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells further highly express CD11c. The present invention provides a CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cell, which infiltrates into a solid tumor. The present invention also provides a pharmaceutical composition containing such a cell population and a pharmaceutically acceptable additive. The present invention further provides a method for producing the aforementioned cell population.
Bibliography:Application Number: EP20190775565